---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027463"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:20:12.919379+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Indaptus completes first Decoy20 cohort; starts second cohort

## Summary
- Three patients completed 28-day safety review; one grade 3 bradycardia (reversible) and two grade 3 AST increases resolved.
- Other adverse events (chills, fatigue, vomiting, fever) were grade 1-2 and resolved quickly.
- Immune activation observed via transient expression of cytokines/chemokines associated with innate and adaptive pathways.
- Second cohort initiated after Safety Review Committee review per protocol.

## SEC filing metadata
- accession: 0001493152-23-027463
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223027463/0001493152-23-027463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223027463/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027463
- JSON: https://secwatch.observer/filing/0001493152-23-027463.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.